American tegumentary leishmaniasis: Is antimonial treatment outcome related to parasite drug susceptibility?

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Infectious Diseases

• Publication date

  2006-10-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1086/507710PMID 16991093
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk factors in the spread of leishmaniases: towards integrated monitoring?

  2006cited by this paper
• Resistance to antimony and treatment failure in human Leishmania (Viannia) infection.

  2006influential reference
• Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia

  2006cited by this paper
• Drug Resistance in Leishmaniasis

  2006cited by this paper
• Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous leishmaniasis in Peru.

  2005cited by this paper
• American tegumentary leishmaniasis: antigen-gene polymorphism, taxonomy and clinical pleomorphism.

  2005cited by this paper
• Role of the ABC Transporter MRPA (PGPA) in Antimony Resistance in Leishmania infantum Axenic and Intracellular Amastigotes

  2005cited by this paper
• Lower Nitric Oxide Susceptibility of Trivalent Antimony-Resistant Amastigotes of Leishmania infantum

  2005cited by this paper
• Culture-Independent Species Typing of Neotropical Leishmania for Clinical Validation of a PCR-Based Assay Targeting Heat Shock Protein 70 Genes

  2004cited by this paper
• Direct identification of Leishmania species in biopsies from patients with American tegumentary leishmaniasis.

  2003cited by this paper
• Antimony-resistant Leishmania donovaniin eastern Sudan: incidence and in vitro correlation.

  2003cited by this paper
• Impact of Habitat Degradation on Phlebotominae (Diptera: Psychodidae) of Tropical Dry Forests in Northern Colombia

  2002cited by this paper
• Infectivity and Virulence of Leishmania donovani Promastigotes: a Role for Media, Source, and Strain of Parasite

  2002cited by this paper
• Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana

  2001cited by this paper
• The increase in risk factors for leishmaniasis worldwide.

  2001cited by this paper
• Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana.

  2001cited by this paper
• High intralesional interleukin-10 messenger RNA expression in localized cutaneous leishmaniasis is associated with unresponsiveness to treatment.

  2001cited by this paper
• Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator.

  2001cited by this paper
• Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species.

  2001influential reference
• Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic.

  2000cited by this paper
• Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

  1999cited by this paper
• Stage-Specific Activity of Pentavalent Antimony against Leishmania donovani Axenic Amastigotes

  1999cited by this paper
• Effect of glucantime on field and patient isolates of New World Leishmania : use of growth parameters of promastigotes to assess antimony susceptibility

  1998cited by this paper
• A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years).

  1997influential reference
• Antimony oxidation states in antileishmanial drugs.

  1995cited by this paper
• In vitro antileishmanial properties of tri- and pentavalent antimonial preparations

  1995cited by this paper
• Diagnosis of Leishmania using the polymerase chain reaction: a simplified procedure for field work.

  1993influential reference
• In vitro cultivation and biological cloning of Leishmania.

  1993cited by this paper
• Vertebral morphometry in women aged 50-81 years.

  1993cited by this paper
• In Vitro Cultivation and Biological Cloning of Leishmania

  1993cited by this paper
• Drug resistance in leishmaniasis: its implication in systemic chemotherapy of cutaneous and mucocutaneous disease.

  1992cited by this paper
• The in vitro Susceptibility of Macrophages Infected with Amastigotes of Leishmania spp. to Pentavalent Antimonial Drugs and Other Compounds with Special Relevance to Cutaneous Isolates

  1989cited by this paper
• Human american cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy.

  1986cited by this paper
• An in-vitro system for determining the activity of compounds against the intracellular amastigote form of Leishmania donovani.

  1984influential reference
• Overproduction of a bifunctional thymidylate synthetase-dihydrofolate reductase and DNA amplification in methotrexate-resistant Leishmania tropica.

  1983influential reference

• Differential Susceptibility to Antimony in Strains and Clinical Isolates of Leishmania amazonensis from Brazil: In Vitro and In Vivo Studies and Implications for Drug Response and Treatment Failure.

  2026cites this paper
• Lack of relationship on in vitro susceptibility of Leishmania (Viannia) braziliensis promastigotes and Leishmania RNA virus 1 to the trivalent antimonial

  2025cites this paper
• Clinical and parasitological features of Leishmania infection among gold miners in the Oiapoque basin, an international Brazil-French Guiana border

  2024cites this paper
• Natural resistance to meglumine antimoniate is associated with treatment failure in cutaneous leishmaniasis caused by Leishmania (Viannia) panamensis

  2024cites this paper
• Imported Cutaneous Leishmaniasis from Peru Caused by Leishmania (Viannia) guyanensis in a Brazilian Patient: Case Report and In Vitro Drug Susceptibility Analysis

  2024cites this paper
• Drug resistance in Leishmania: does it really matter?

  2023cites this paper
• Leishmanicidal and healing effects of 3β,6β,16β-trihydroxy lup-20 (29)-ene isolated from Combretum leprosum on Leishmania braziliensis infection in vitro and in vivo

  2023cites this paper
• Unveiling drug-tolerant and persister-like cells in Leishmania braziliensis lines derived from patients with cutaneous leishmaniasis

  2023cites this paper
• In vitro miltefosine and amphotericin B susceptibility of strains and clinical isolates of Leishmania species endemic in Brazil that cause tegumentary leishmaniasis.

  2023cites this paper
• Selective whole-genome amplification reveals population genetics of Leishmania braziliensis directly from patient skin biopsies

  2022cites this paper
• Sensitive and specific serodiagnosis of tegumentary leishmaniasis using a new chimeric protein based on specific B-cell epitopes of Leishmania antigenic proteins

  2022cites this paper
• Diversity and Within-Host Evolution of Leishmania donovani from Visceral Leishmaniasis Patients with and without HIV Coinfection in Northern Ethiopia

  2021cites this paper
• A “Golden Age” for the discovery of new antileishmanial agents: Current status of leishmanicidal gold complexes and prospective targets beyond the trypanothione system

  2021cites this paper
• The study of P-glycoprotein A, G-glutamylcysteine synthetase 1, and aquaglyceroporin 1 genes expression in non-healing zoonotic cutaneous leishmaniasis cases

  2021cites this paper
• The effects of medicinal herbs and marine natural products on wound healing of cutaneous leishmaniasis: A systematic review.

  2021cites this paper
• Comparative analysis of the transcriptional responses of five Leishmania species to trivalent antimony

  2021cites this paper
• Diversity and within-host evolution of parasites from VL and VL/HIV patients in Northern Ethiopia

  2021cites this paper
• Transcriptional Shift and Metabolic Adaptations during Leishmania Quiescence Using Stationary Phase and Drug Pressure as Models

  2021cites this paper
• Insights from Leishmania (Viannia) guyanensis in vitro behavior and intercellular communication

  2021cites this paper
• Activity of paromomycin against Leishmania amazonensis: Direct correlation between susceptibility in vitro and the treatment outcome in vivo

  2020cites this paper
• CpG ODN D35 improves the response to abbreviated low-dose pentavalent antimonial treatment in non-human primate model of cutaneous leishmaniasis

  2020cites this paper
• Application of CRISPR/Cas9-Based Reverse Genetics in Leishmania braziliensis: Conserved Roles for HSP100 and HSP23

  2020cites this paper
• Susceptibility to paromomycin in clinical isolates and reference strains of Leishmania species responsible for tegumentary leishmaniasis in Brazil.

  2020cites this paper
• In vitro activity and mode of action of phenolic compounds on Leishmania donovani

  2019cites this paper
• Ecological divergence and hybridization of Neotropical Leishmania parasites

  2019cites this paper
• Identifying miltefosine-resistant key genes in protein–protein interactions network and experimental verification in Iranian Leishmania major

  2019cites this paper
• Tracking of quiescence in Leishmania by quantifying the expression of GFP in the ribosomal DNA locus

  2019cites this paper
• Meta-analysis and discussion on challenges to translate Leishmania drug resistance phenotyping into the clinic.

  2019cites this paper
• Epidemiology of Leishmaniasis in the Time of Drug Resistance (the Miltefosine Era)

  2018cites this paper
• Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria

  2018cites this paper
• Efficacy of Apigenin and Miltefosine Combination Therapy against Experimental Cutaneous Leishmaniasis.

  2018cites this paper
• Evaluation of Correlation between the In Vitro Susceptibility of Field Isolates of Leishmania major and Clinical Outcomes of Meglumine Antimoniate Therapy in Fars Province, Iran

  2017cites this paper
• Leishmania antimony resistance/ susceptibility in Algerian foci

  2017cites this paper
• In Vitro Sensitivity of Cutaneous Leishmania Promastigote Isolates Circulating in French Guiana to a Set of Drugs.

  2017cites this paper
• Low versus high dose of antimony for American cutaneous leishmaniasis: A randomized controlled blind non-inferiority trial in Rio de Janeiro, Brazil

  2017cites this paper
• Etude de la chimiorésastance aux antimoniés chez leishmania en Algerie : Validation des tests in vitro et développement de marqueurs moléculaires

  2016cites this paper
• Evaluating drug resistance in visceral leishmaniasis: the challenges

  2016cites this paper
• Association of the Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis Caused by Leishmania braziliensis in Peru and Bolivia.

  2016influential citation
• Intralesional Pentamidine: A Novel Therapy for Single Lesions of Bolivian Cutaneous Leishmaniasis.

  2016cites this paper
• Miltefosine Susceptibility and Resistance in Leishmania: From the Laboratory to the Field

  2016cites this paper
• Intrachromosomal Amplification, Locus Deletion and Point Mutation in the Aquaglyceroporin AQP1 Gene in Antimony Resistant Leishmania (Viannia) guyanensis

  2015cites this paper
• Avaliation the Therapeutic Efficacy of Fluconazol

  2015cites this paper
• In-vitro sensitivity of Pakistani Leishmania tropica field isolate against buparvaquone in comparison to standard anti-leishmanial drugs.

  2015cites this paper
• In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model

  2015cites this paper
• In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis

  2014cites this paper
• Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race.

  2014cites this paper
• Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?

  2014influential citation
• Falla terapéutica y hepatotoxicidad de los esquemas de tratamiento endovenoso e intramuscular con estibogluconato de sodio en pacientes con leishmaniasis cutánea

  2014cites this paper
• Arsenic, antimony and visceral leishmaniasis

  2014cites this paper
• Leishmaniasis transmission biology: Role of Promastigote Secretory Gel as a transmission determinant

  2014cites this paper
• Epidémiologie moléculaire de la résistance de Leishmania aux antimoniés en France et au Maghreb

  2014cites this paper
• Novel approaches for the identification of inhibitors of leishmanial dipeptidylcarboxypeptidase

  2013cites this paper
• University of Dundee A novel marker , ARM 58 , confers antimony resistance to Leishmania spp

  2013cites this paper
• Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model.

  2013influential citation
• Epidemiology of Leishmaniasis in the Time of Drug Resistance

  2013cites this paper
• Simultaneous infection with Leishmania (Viannia) braziliensis and L. (V.) lainsoni in a Peruvian patient with cutaneous leishmaniasis.

  2013cites this paper
• American Tegumentary Leishmaniasis

  2013cites this paper
• Intracellular Mechanisms of Resistance

  2013cites this paper
• Chronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis

  2013cites this paper
• Retrospective and ongoing researches on Leishmania antimony resistance in Algeria

  2013cites this paper
• Estudo comparativo entre o antimoniato-N-metilglucamina (Glucantime®) e o isotionato de pentamidina (Pentacarinat®) em lesões cutâneas da leishmaniose tegumentar

  2013cites this paper
• Role of Efflux Pumps and Intracellular Thiols in Natural Antimony Resistant Isolates of Leishmania donovani

  2013cites this paper
• Clinical pharmacology in leishmaniasis: treatment optimization of a neglected disease

  2013cites this paper
• The Relevance of Susceptibility Tests, Breakpoints, and Markers

  2013cites this paper
• A novel marker, ARM58, confers antimony resistance to Leishmania spp.

  2013influential citation
• Avaliação da atividade in vivo do antimoniato de meglumina e de sua associação com o tratamento tópico sobre Leishmania (Viannia) braziliensis isoladas de pacientes portadores de leishmaniose cutânea

  2012cites this paper
• Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations Vary with Genetic Background

  2012cites this paper
• In Vitro and In Vivo Efficacy of Ether Lipid Edelfosine against Leishmania spp. and SbV-Resistant Parasites

  2012cites this paper
• A novel approach to in vitro drug susceptibility assessment of clinical strains of

  2012cites this paper
• Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani

  2012cites this paper
• Novel Approach to In Vitro Drug Susceptibility Assessment of Clinical Strains of Leishmania spp

  2012cites this paper
• Susceptibility Test Methods: Parasites

  2011cites this paper
• Increased metacyclogenesis of antimony-resistant Leishmania donovani clinical lines

  2011cites this paper
• Mechanisms of Resistance to Antiparasitic Agents

  2011cites this paper
• Multilocus genotyping reveals a polyphyletic pattern among naturally antimony-resistant Leishmania braziliensis isolates from Peru.

  2011influential citation
• Leishmania antimony resistance: what we know what we can learn from the field

  2011cites this paper
• Downregulation of Mitogen-Activated Protein Kinase 1 of Leishmania donovani Field Isolates Is Associated with Antimony Resistance

  2011cites this paper
• Comparative Gene Expression Analysis throughout the Life Cycle of Leishmania braziliensis: Diversity of Expression Profiles among Clinical Isolates

  2011cites this paper
• Antimony Resistance in Leishmania, Focusing on Experimental Research

  2011cites this paper
• Gene Expression Profiling and Molecular Characterization of Antimony Resistance in Leishmania amazonensis

  2011cites this paper
• Drug susceptibility of Leishmania infantum (syn. Leishmania chagasi) isolates from Brazilian HIV-positive and HIV-negative patients.

  2011cites this paper
• The fitness of antimony-resistant Leishmania parasites: lessons from the field.

  2011cites this paper
• Comparison of gene expression patterns among Leishmania braziliensis clinical isolates showing a different in vitro susceptibility to pentavalent antimony

  2010influential citation
• Overexpression of histone H2A modulates drug susceptibility in Leishmania parasites.

  2010cites this paper
• Targeted gene expression profiling in Leishmania braziliensis and Leishmania guyanensis parasites isolated from Brazilian patients with different antimonial treatment outcomes.

  2010cites this paper
• Studies of Gene Expression in Drug Resistant Leishmania donovani using DNA Microarrays

  2010cites this paper
• In Vitro Sensitivity Testing of Leishmania Clinical Field Isolates: Preconditioning of Promastigotes Enhances Infectivity for Macrophage Host Cells

  2009influential citation
• Cellular immune response profile in patients with American tegumentary leishmaniasis prior and post chemotherapy treatment

  2009cites this paper
• Identificação molecular das espécies de leishmânia em lesões cutâneas de pacientes atendidos no Centro de Controle de Zoonoses de Santarém, Pará

  2009cites this paper
• Leishmaniases in Bolivia: comprehensive review and current status.

  2009cites this paper
• Drug Resistance Assays for Parasites

  2009cites this paper
• Comparative Efficacies of Two Antimony Regimens To Treat Leishmania braziliensis-Induced Cutaneous Leishmaniasis in Rhesus Macaques (Macaca mulatta)

  2009cites this paper
• In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B

  2009influential citation
• Immunological Determinants of Clinical Outcome in Peruvian Patients with Tegumentary Leishmaniasis Treated with Pentavalent Antimonials

  2009cites this paper
• Desenvolvimento de espécies de Leishmania fluorescentes e caracterização da susceptibilidade de L. amazonensis GFP como modelo para testes quimioterápicos Por

  2009cites this paper
• CARACTERIZAÇÃO DA RESPOSTA IMUNE CELULAR EM PORTADORES DE LEISHMANIOSE TEGUMENTAR AMERICANA ANTES E APÓS TRATAMENTO QUIMIOTERÁPICO

  2008cites this paper
• Efecto fototóxico de la terapia fotodinámica en promastigotes de Leishmania amazonensis

  2008cites this paper
• Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.

  2008cites this paper
• Leishmaniases in the Mediterranean in the era of molecular epidemiology.

  2008cites this paper
• Studies on oligopeptidase B of Leishmania major

  2008cites this paper